Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Panuveitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Panuveitis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-011237-27 Sponsor Protocol Number: CAIN457C2303 Start Date*: 2009-10-15
    Sponsor Name:Novartis Pharma Services Ag
    Full Title: A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated ...
    Medical condition: Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) FR (Completed) DE (Completed) AT (Prematurely Ended) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003254-90 Sponsor Protocol Number: CLFG316A2204 Start Date*: 2012-05-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomised, active-controlled, open-label, multiple-dose, proof-of-concept study of intravitreal LFG316 in patients with active non-infectious intermediate-, posterior-, or panuveitis requiring s...
    Medical condition: Active non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000161411 10022557 Intermediate uveitis LLT
    20.0 100000014975 10033687 Panuveitis LLT
    20.0 100000015065 10036370 Posterior uveitis LLT
    20.0 100000014975 10066681 Acute uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016008-22 Sponsor Protocol Number: M10-880 Start Date*: 2010-07-19
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis
    Medical condition: Inactive non-infectious intermediate-, posterior-, or pan-uveitis.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022557 Intermediate uveitis LLT
    12.1 10033687 Panuveitis LLT
    12.1 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) BE (Completed) PT (Completed) GB (Completed) NL (Completed) DE (Completed) DK (Completed) AT (Completed) IT (Completed) CZ (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014835-19 Sponsor Protocol Number: CAIN457C2301 Start Date*: 2010-02-15
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio Fase III, multicéntrico, aleatorizado con doble enmascaramiento, controlado con placebo, de determinación de dosis y 24 semanas de duración, con el objetivo de evaluar el AIN457 frente a pl...
    Medical condition: Demostrar la eficacia y seguridad de AIN457 como terapia adyuvante en el tratamiento de la uveitis intermedia, uveitis posterior o panuveitis que precise inmunosupresión sistémica.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10022941 Iridocyclitis LLT
    9 10022557 Intermediate uveitis LLT
    9 10033687 Panuveitis LLT
    9 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003612-53 Sponsor Protocol Number: LIGS4001 Start Date*: 2008-07-25
    Sponsor Name:National Institutes of Health, National Eye Institute
    Full Title: Multicenter Uveitis Steroid Treatment Trial
    Medical condition: Non-infectious uveitis (inflammatory eye disease)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046851 Uveitis LLT
    9.1 10033687 Panuveitis LLT
    9.1 10022557 Intermediate uveitis LLT
    9.1 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016095-68 Sponsor Protocol Number: M10-877 Start Date*: 2010-07-19
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non infectious...
    Medical condition: Active Non-infectious Intermediate-, Posterior-, or Pan-uveitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022557 Intermediate uveitis LLT
    12.1 10033687 Panuveitis LLT
    12.1 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) BE (Completed) PT (Completed) GB (Completed) NL (Completed) DE (Completed) DK (Completed) AT (Completed) IT (Completed) CZ (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014834-22 Sponsor Protocol Number: CAIN457C2302 Start Date*: 2010-07-06
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio Fase III, multicéntrico, aleatorizado con doble enmascaramiento, controlado con placebo, de determinación de dosis y 28 semanas de duración, para evaluar AIN457 frente a placebo en la induc...
    Medical condition: determinación de dosis y 28 semanas de duración, para evaluar AIN457 frente a placebo en la inducción y mantenimiento de la supresión de la uveítis en adultos con uveítis activa no infecciosa inter...
    Disease: Version SOC Term Classification Code Term Level
    11 10022557 Uveítis intermedia PT
    11 10036370 Uveítis posterior LLT
    11 10033687 Panuveítis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) HU (Prematurely Ended) GB (Completed) DE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016196-29 Sponsor Protocol Number: M11-327 Start Date*: 2010-07-19
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Non-infectious Intermediate-, Posterior-, or Pan-uveitis
    Medical condition: Non-infectious Intermediate-, Posterior-, or Pan-uveitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022557 Intermediate uveitis LLT
    12.1 10033687 Panuveitis LLT
    12.1 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) BE (Completed) PT (Completed) GB (Completed) DE (Completed) DK (Completed) AT (Completed) IT (Completed) CZ (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-015508-24 Sponsor Protocol Number: CAIN457C2301E1 Start Date*: 2010-02-15
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Extensión de 38 semanas del Estudio Fase III, multicéntrico, aleatorizado con doble enmascaramiento, controlado con placebo, de determinación de dosis y 24 semanas de duración, con el objetivo de e...
    Medical condition: Terapia adyuvante para el tratamiento de uveitis intermedia, uveitis posterior o panuveitis que precisen inmunosupresión sistémica
    Disease: Version SOC Term Classification Code Term Level
    12.0 10022941 Iridocyclitis LLT
    9 10022557 Intermediate uveitis LLT
    9 10033687 Panuveitis LLT
    9 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013901-33 Sponsor Protocol Number: CAIN457C2303E1 Start Date*: 2009-11-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior...
    Medical condition: Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001243-67 Sponsor Protocol Number: CAIN457A2208 Start Date*: 2011-07-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label proof-of-concept study with a double-masked, dose-ranging component to assess the effects of AIN457 in patients with noninfectious uveitis
    Medical condition: Intermediate, posterior or pan-uveitis of noninfectious origin
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    14.0 10015919 - Eye disorders 10036370 Posterior uveitis LLT
    14.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001078-25 Sponsor Protocol Number: H.34.04.04.07.B1 Start Date*: 2011-11-07
    Sponsor Name:National Institute of Health, National Eye Institute
    Full Title: Long-term Follow-up of Patients Who Participated in the Multicenter Uveitis Steroid Treatment Trial (MUST Trial Follow-up Study).
    Medical condition: Non-infectious pan, intermediate and posterior uveitis (inflammatory eye disease)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    14.0 10015919 - Eye disorders 10046851 Uveitis PT
    14.0 10015919 - Eye disorders 10036370 Posterior uveitis LLT
    14.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-006498-49 Sponsor Protocol Number: 21103 Start Date*: 2022-08-18
    Sponsor Name:ACELYRIN, Inc.
    Full Title: A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis
    Medical condition: Non-infectious, Intermediate-, Posterior- or Pan-uveitis
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004853 10022557 Intermediate uveitis LLT
    20.1 100000004862 10036370 Posterior uveitis LLT
    20.0 100000004853 10033687 Panuveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001485-17 Sponsor Protocol Number: GS-US-432-4097 Start Date*: 2017-08-15
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Active Non-Infectious Uveitis
    Medical condition: Non-infectious Uveitis
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004853 10022557 Intermediate uveitis LLT
    20.1 100000004862 10036370 Posterior uveitis LLT
    20.0 100000004853 10033687 Panuveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2012-001610-42 Sponsor Protocol Number: X052130/CL3-78989-005 Start Date*: 2013-01-24
    Sponsor Name:XOMA (US) LLC
    Full Title: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
    Medical condition: Non-infectious Intermediate, Posterior, or Pan- Uveitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    17.0 10038359 - Renal and urinary disorders 10069034 Tubulointerstitial nephritis and uveitis syndrome PT
    17.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    17.0 100000004862 10036370 Posterior uveitis LLT
    17.0 10015919 - Eye disorders 10066681 Acute uveitis LLT
    17.0 100000004866 10071139 Behcet's uveitis LLT
    17.0 10015919 - Eye disorders 10042745 Sympathetic uveitis LLT
    17.0 10015919 - Eye disorders 10012692 Diabetic uveitis PT
    17.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Completed) GB (Prematurely Ended) ES (Completed) GR (Prematurely Ended) AT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015509-38 Sponsor Protocol Number: CAIN457C2302E1 Start Date*: 2010-10-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 34-week extension to a 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppres...
    Medical condition: Non-infectious, intermediate uveitis, posterior uveitis or panuveitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000304-29 Sponsor Protocol Number: Start Date*: 2016-04-05
    Sponsor Name:MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health
    Full Title: Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial
    Medical condition: Uveitic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014995 10002709 Anterior uveitis LLT
    20.0 100000161411 10022557 Intermediate uveitis LLT
    20.0 100000014975 10033687 Panuveitis LLT
    20.0 100000015065 10036370 Posterior uveitis LLT
    20.0 10015919 - Eye disorders 10058202 Cystoid macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003243-37 Sponsor Protocol Number: Start Date*: 2017-11-02
    Sponsor Name:MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health
    Full Title: Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial
    Medical condition: Uveitic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10002709 Anterior uveitis LLT
    22.1 10015919 - Eye disorders 10022557 Intermediate uveitis LLT
    20.1 100000004862 10036370 Posterior uveitis LLT
    20.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    20.1 10015919 - Eye disorders 10058202 Cystoid macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2006-006545-13 Sponsor Protocol Number: LX211-03-UV Start Date*: 2007-04-27
    Sponsor Name:Lux Biosciences GmbH
    Full Title: A Double-Masked, Placebo-Controlled, Multi-Centre, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Uveitis.
    Medical condition: Subjects with active sight-threatening, non-infectious anterior, anterior and intermediate- or panuveitis who require systemic immunosuppression for the control of their disease.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006543-31 Sponsor Protocol Number: LX211-01-UV Start Date*: 2007-04-13
    Sponsor Name:Lux Biosciences GmbH
    Full Title: A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study with an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight ...
    Medical condition: Subjects with active sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 03:34:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA